Andrew W. Adams (HC) is a Co-Founder and Managing Partner of Oak HC/FT, focusing on growth equity and early-stage venture opportunities in Healthcare.
Andrew currently serves on the Boards of August Bioservices, Curana Health, DispatchHealth, Eating Recovery Center, Everside Health, Galileo, Infusion for Health, Reveleer, Rialtic, Unified Women’s Healthcare, US HealthVest, Veda, and WithMe Health. Andrew is also actively involved with Noom and Precision Medicine Group.
Prior investments include Core Informatics (acquired by Thermo Fischer), LDI (acquired by Diplomat Pharmacy), Limeade (ASX: LME), Maestro Health (acquired by AXA Group), One Medical Group (NASDAQ: ONEM) and Therapy Brands (acquired by KKR). Other prior investments include American Esoteric Laboratories (acquired by Sonic Healthcare Limited), Argus Information & Advisory Services (acquired by Verisk Analytics), Benefitfocus (NASDAQ: BNFT), CareMedic Systems (acquired by Ingenix), CLARiENT (acquired by GE Healthcare), Health Dialog (acquired by British United Provident Association), iHealth Technologies (merged with Connolly), Independent Living Systems, NetSpend Corporation (acquired by TSYS), PayFlex Systems (acquired by Aetna), PharMEDium Healthcare (acquired by CD&R) and United BioSource (acquired by Medco Health Solutions).
Andrew has more than 25 years of experience in Healthcare investing. He began his career as an Analyst at Deutsche Banc Alex. Brown.
Andrew received a Bachelor of Arts degree from Princeton University.